Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Characterizing the Role that Hypoxia has on the Rate and Efficiency of Angiogenesis using Modular Tissue Constructs

FY 2013-14

Summary
Almost 300 million people worldwide have been diagnosed with diabetes. In Canada, 10% of those diagnosed have type I diabetes, a figure that continues to increase every year. Type I diabetes is an autoimmune disease caused by the self-degradation of the insulin-producing beta cells of the pancreas. A type I diagnosis shortens an individuals life expectancy by up to 15 years and introduce risk of severe complications, such as stroke, heart disease, amputations and kidney disease. Pancreas transplantations are an effective long-term treatment for individuals with type I diabetes, but treatments are limited by a lack of donors. An emerging therapy that has shown to help regulate the levels of blood glucose and alleviate some of the symptoms associated with type I diabetes is the transplantation of therapeutic cells, such as pancreatic islets. Although this treatment has shown promise, the low transplantation success of the pancreatic islets has limited its therapeutic effectiveness. A current focus in the field of tissue engineering is the use of complex tissue implants to increase the transplantation success of therapeutic cells by stimulating the development of blood vessels at the site of implantation. Modular tissue implants, developed by the Sefton lab, contain two different cell types: a vascular-support cell (mesenchymal stromal cell - MSC) and a functional cell (endothelial cell - EC). These modular implants have been shown to integrate with the host’s vasculature network and stimulate the formation of blood vessels after implantation. The formation of these blood vessels is governed by a process known as angiogenesis; the formation of new blood vessels from pre-existing vessels. Preliminary work in the Sefton lab observed that increasing the tissue implant volume resulted in an increase in the number of graft cell-derived vessels. In addition, there was an observed increase in the expression of Hypoxia Inducible Factor 1 (HIF-1), a protein activated in response to a low oxygen environment (hypoxia). Expression of HIF-1 activates pro-angiogenic molecules, known as growth factors, which stimulates angiogenesis. This increase in the expression of HIF-1 suggests that hypoxia is a driver of new vessel formation in the larger implants. Therefore, we hypothesize that the hypoxia pathway can be exploited to promote rapid vessel formation to increase engraftment success of our functional modular tissue constructs. Using a series of co-culture experiments, we will analyze the cellular response of MSCs and ECs to hypoxia. The induction of hypoxia will be achieved using a chemical mimic to ensure reproducible conditions. We will monitor the expression of HIF-1 and hypoxia-induced genes in response to activation of hypoxia. ECs and MSCs will be tested separately and together, allowing us to monitor the effect of hypoxia on the cell-cell interactions between the two cell populations. Finally, constructs will be implanted in a 3-D fibrin gel (as in a sprouting assay) to observe endothelial cell migration and sprout formation, two processes that occur during angiogenesis. We will induce hypoxia at different time points to monitor any effects on sprout formation and cell migration. Successful completion of the proposed work will provide insights on a set of parameters and targets that can be modified in our existing module system to enhance the degree and rate of graft cell-derived vessel formation. The increased vessel formation at the site of implantation will increase the therapeutic potential and efficiency of therapeutic cell transplantation of our modular construct model.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311796
Name
Vlahos Alexander E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing the Role that Hypoxia has on the Rate and Efficiency of Angiogenesis using Modular Tissue Constructs
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Artificial Tissue/Implant; Diabetes Mellitus; Endothelial Cells; Hypoxia; Modular Tissue Constructs; Pancreatic Islets; Regenerative Medicine; Tissue Engineering; Vascularization
Abstract
Almost 300 million people worldwide have been diagnosed with diabetes. In Canada, 10% of those diagnosed have type I diabetes, a figure that continues to increase every year. Type I diabetes is an autoimmune disease caused by the self-degradation of the insulin-producing beta cells of the pancreas. A type I diagnosis shortens an individuals life expectancy by up to 15 years and introduce risk of severe complications, such as stroke, heart disease, amputations and kidney disease. Pancreas transplantations are an effective long-term treatment for individuals with type I diabetes, but treatments are limited by a lack of donors. An emerging therapy that has shown to help regulate the levels of blood glucose and alleviate some of the symptoms associated with type I diabetes is the transplantation of therapeutic cells, such as pancreatic islets. Although this treatment has shown promise, the low transplantation success of the pancreatic islets has limited its therapeutic effectiveness. A current focus in the field of tissue engineering is the use of complex tissue implants to increase the transplantation success of therapeutic cells by stimulating the development of blood vessels at the site of implantation. Modular tissue implants, developed by the Sefton lab, contain two different cell types: a vascular-support cell (mesenchymal stromal cell - MSC) and a functional cell (endothelial cell - EC). These modular implants have been shown to integrate with the host’s vasculature network and stimulate the formation of blood vessels after implantation. The formation of these blood vessels is governed by a process known as angiogenesis; the formation of new blood vessels from pre-existing vessels. Preliminary work in the Sefton lab observed that increasing the tissue implant volume resulted in an increase in the number of graft cell-derived vessels. In addition, there was an observed increase in the expression of Hypoxia Inducible Factor 1 (HIF-1), a protein activated in response to a low oxygen environment (hypoxia). Expression of HIF-1 activates pro-angiogenic molecules, known as growth factors, which stimulates angiogenesis. This increase in the expression of HIF-1 suggests that hypoxia is a driver of new vessel formation in the larger implants. Therefore, we hypothesize that the hypoxia pathway can be exploited to promote rapid vessel formation to increase engraftment success of our functional modular tissue constructs. Using a series of co-culture experiments, we will analyze the cellular response of MSCs and ECs to hypoxia. The induction of hypoxia will be achieved using a chemical mimic to ensure reproducible conditions. We will monitor the expression of HIF-1 and hypoxia-induced genes in response to activation of hypoxia. ECs and MSCs will be tested separately and together, allowing us to monitor the effect of hypoxia on the cell-cell interactions between the two cell populations. Finally, constructs will be implanted in a 3-D fibrin gel (as in a sprouting assay) to observe endothelial cell migration and sprout formation, two processes that occur during angiogenesis. We will induce hypoxia at different time points to monitor any effects on sprout formation and cell migration. Successful completion of the proposed work will provide insights on a set of parameters and targets that can be modified in our existing module system to enhance the degree and rate of graft cell-derived vessel formation. The increased vessel formation at the site of implantation will increase the therapeutic potential and efficiency of therapeutic cell transplantation of our modular construct model.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vlahos, Alexander E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~